3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
11
Radiotherapy
11
Filgrastim
6
Granulocyte Colony-Stimulating Factor
4
Chemotherapy, Adjuvant
4
etoposide phosphate
3
Topotecan
3
O(6)-benzylguanine
3
Melphalan
3
Etoposide
3
Cyclophosphamide
3
Carboplatin
3
sodium thiosulfate
2
sargramostim
2
Thiotepa
2
Radiotherapy, Intensity-Modulated
2
Methylphenidate
2
Mannitol
2
Ifosfamide
2
Carmustine
2
Busulfan
2
Bone Marrow Transplantation
2
Bevacizumab
2
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
temsirolimus
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
poly ICLC
1
pentetreotide
1
pemigatinib
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Central Nervous System Neoplasms
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts